By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

VBL Therapeutics 

6 Jonathan Netanyahu Street

Or Yehuda    60376  Israel
Phone: 97-236-346450 Fax: 97-236-346449


SEARCH JOBS


Industry
Biotechnology






Company News
Newly Granted U.S. Composition Of Matter Patent Extends Exclusive Protection For VBL Therapeutics (VBLX)' Lead Drug Candidate VB-111 Until October 2033 12/1/2015 7:29:44 AM
VBL Therapeutics (VBLX) Announces Significant Improvement Of 12 Month Overall Survival With VB-111 Compared To Pooled Data From Four Avastin Studies At The Annual Meeting Of The Society For Neuro-Oncology 11/19/2015 7:50:09 AM
VBL Therapeutics (VBLX) Data On VB-111 In Combination With Bevacizumab To Be Presented At The Annual Meeting Of The Society For Neuro-Oncology 11/16/2015 7:46:19 AM
VBL Therapeutics (VBLX) Announces Third Quarter 2015 Financial Results And Provides Business Update 11/12/2015 7:25:54 AM
VBL Therapeutics (VBLX) To Report Third Quarter 2015 Financial Results On November 12 11/5/2015 10:08:06 AM
VBL Therapeutics (VBLX) Presents Positive Data On VB-111 In Advanced Radioactive Iodine Refractory Differentiated Thyroid Cancer At The ITC 2015 Conference 10/22/2015 7:33:16 AM
VBL Therapeutics (VBLX) Reports Full Phase 2 Data From Clinical Trial Of VB-111 In Recurrent Glioblastoma (rGBM) At The ECC 2015 Conference, Meeting The Primary Endpoint Of Statistically-Significant Increase In Overall Survival 9/28/2015 6:29:27 AM
VBL Therapeutics (VBLX) To Present Complete Phase 2 Data On VB-111 In Combination With Bevacizumab In Recurrent GBM At The European Cancer Conference 9/18/2015 6:38:44 AM
VBL Therapeutics (VBLX) Announces First Patient Dosed In Pivotal Phase III Trial Of VB-111 In Recurrent Glioblastoma 8/20/2015 7:52:06 AM
VBL Therapeutics (VBLX) Announces Second Quarter 2015 Financial Results And Provides Business Update 8/13/2015 10:01:25 AM
12345678
//-->